RT Journal Article
SR Electronic
T1 Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5089
OP 5096
DO 10.21873/anticanres.13703
VO 39
IS 9
A1 MORINE, YUJI
A1 IKEMOTO, TETSUYA
A1 IWAHASHI, SHUICHI
A1 SAITO, YU
A1 YAMADA, SHINICHIRO
A1 TAKASU, CHIE
A1 HIGASHIJIMA, JUN
A1 IMURA, SATORU
A1 SHIMADA, MITSUO
YR 2019
UL http://ar.iiarjournals.org/content/39/9/5089.abstract
AB Background/Aim: We evaluated the clinical impact of FOLFOXIRI regimen aiming for conversion surgery in patients with unresectable multiple colorectal liver metastasis (CRLM). Patients and Methods: A total of 42 patients with unresectable multiple CRLM who received chemotherapy with molecular agents were included in the analysis. The clinical results of FOLFOXIRI with other regimens were compared. Results: The total conversion rate of 42 unresectable CRLM was 48.1%, and conversion cases had a better prognosis. Clinicopathological characteristics of conversion cases were more frequent in FOLFOXIRI induction, liver limited disease and maximum diameter × number (MDN) over 70. FOLFOXIRI achieved a higher conversion rate compared to other regimens (72.2% vs. 37.5%, p=0.0334), and significantly reduced the medication period until conversion surgery (median 5.8 courses) with a higher tumour necrotic rate. Consequently, the overall survival of conversion cases with FOLFOXIRI was better than that with other regimens (p=0.0055). Conclusion: FOLFOXIRI plus molecular agents might provide a higher probability of conversion surgery with a prognostic benefit.